Prognostic role of pan-immune-inflammation value in patients with metastatic castration-resistant prostate cancer treated with androgen receptor-signaling inhibitors.

Satı Coşkun YazganEmre YekedüzGüngör UtkanYuksel Urun

Published in: The Prostate (2022)

In this study, we demonstrated that PIV was an independent prognostic factor for OS in patients with mCRPC treated with AA or enzalutamide. Additionally, PIV-LDH combined score may be considered a promising composite peripheral blood-based biomarker to predict OS in those patients.

Keyphrases

prognostic factors
peripheral blood
newly diagnosed
end stage renal disease
prostate cancer
ejection fraction
oxidative stress
chronic kidney disease
peritoneal dialysis
patient reported outcomes